Sinobioway Biomedicine-B (02627): The IND of recombinant respiratory syncytial virus vaccine (CHO cells) (adjuvant) has been approved by China CDE and US FDA.

Chinatimes Financial News App reports that Sinovac Biotech Ltd. -B (02627) has announced that the new drug clinical trial application (IND) for the recombinant respiratory syncytial virus vaccine (CHO cells) (adjuvant) developed independently by the group has been approved by the Center for Drug Evaluation (CDE) of the National Medical Products Administration. In addition, the IND application for this vaccine in the United States has also been approved by the Food and Drug Administration (FDA).